CRISPR Therapeutics and Vertex Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Tuesday, September 27, 2022 1 min read

Key Takeaway: CRISPR Therapeutics and Vertex Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Full Press Release Details

CRISPR Therapeutics and Vertex Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022.